Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 120.46 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Neurocrine Bioscienc < Previous 1 2 3 4 5 6 7 8 9 Next > NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. September 19, 2024 Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase. Via Chartmill Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint September 13, 2024 Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in treating cognitive impairment in schizophrenia. The company will halt development... Via Benzinga Decoding 19 Analyst Evaluations For Neurocrine Biosciences September 09, 2024 Via Benzinga NASDAQ:NBIX, a growth stock which is not overvalued. September 09, 2024 Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. Via Chartmill Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio? September 08, 2024 10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences. Via Benzinga Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts August 19, 2024 Via Benzinga NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. August 19, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. Via Chartmill NASDAQ:NBIX is not too expensive for the growth it is showing. August 19, 2024 Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. Via Chartmill Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag. September 05, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a stock that provides good value for the fundamentals it showcases. Via Chartmill Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio? September 02, 2024 10 worst performing large-cap stocks in the last week. Dollar General, Super Micro Computer, Okta, Pure Storage, Neurocrine Biosciences among them. Via Benzinga Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review August 30, 2024 The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. Via Investor's Business Daily Topics Stocks Exposures US Equities Why Neurocrine Biosciences Stock Was Tumbling This Week August 30, 2024 The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea. Via The Motley Fool A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences August 01, 2024 Via Benzinga NASDAQ:NBIX, a strong growth stock, setting up for a breakout. July 26, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. Via Chartmill Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock August 29, 2024 Neurocrine Biosciences reports positive Phase 2 trial results for NBI-1117568 in adults with schizophrenia, showing significant reduction in PANSS scores with a 20 mg dose. Piper Sandler upgrades the... Via Benzinga NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday August 29, 2024 Via Benzinga Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results August 28, 2024 Via Benzinga As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors August 28, 2024 Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose. Via Benzinga US Stocks Mixed; JM Smucker Slashes Annual Guidance August 28, 2024 Via Benzinga NASDAQ:NBIX, a growth stock which is not overvalued. July 26, 2024 Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. Via Chartmill Should Quality Investors Include NASDAQ:NBIX in Their Portfolio? July 25, 2024 Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive. Via Chartmill Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers August 28, 2024 As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial. Via Investor's Business Daily Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna August 27, 2024 Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. Via Benzinga Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). August 22, 2024 Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) suited for quality investing? Via Chartmill 9 Health Care Stocks Whale Activity In Today's Session August 13, 2024 Via Benzinga New Study Reveals How Classical Music Could Revolutionize Depression Care August 12, 2024 In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... Via PressReach Exposures Product Safety Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences July 10, 2024 Via Benzinga So Much For Expecting The Fed To Stick The Landing August 04, 2024 Now is not the time to be fully invested. Via Talk Markets Topics Economy Exposures Interest Rates Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review August 02, 2024 Apple and Meta had strong results, while AI spending remains robust. Via Investor's Business Daily Topics Artificial Intelligence Exposures Artificial Intelligence Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. July 05, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout. Via Chartmill < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.